Novartis, working to improve Alcon, gives back ThromboGenics drug Jetrea

Eye
At one time, analysts had projected Jetrea could hit about $500 million in annual sales, but in the first half of the year, ThromboGenics reported only about $3.2 million in sales.

Novartis, which has been trying to fix its struggling Alcon eye unit, figures that process will be easier without a floundering eye medication in the portfolio. Accordingly, it has returned the rights to Jetrea to ThromboGenics.

The Leuven, Belgium-based ThromboGenics today said the companies had “mutually” agreed the drug would be better in the biotech’s hands. Novartis has sold Jetrea since 2012 outside of the the U.S. where it is approved as a treatment for vitreomacular traction.

As part of the unbundling, ThromboGenics will pick up some badly needed cash, a payment of €53.7 million. Novartis also agreed to invest another €10 million in the company’s shares, which the Belgium company said it would use to develop its portfolio of drugs for treating diabetic eye disease. The company reported a €15.2 million loss in H1.  

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales

“We intend to take time to evaluate how best to capitalize on the global opportunity that we now have with Jetrea. In the near term,” CEO Patrik De Haes said in a statement.

So far the opportunity for the drug has been small. At one time, analysts had projected it could hit about $500 million in annual sales, but in the first half of the year, ThromboGenics reported only about $3.2 million in Jetrea sales, including about $956,000 from Novartis royalties. Last year, the company recorded about $7.8 million in Jetrea sales.

RELATED: Novartis gets boost from an unexpected source—Alcon—as generic pricing sinks Sandoz sales

As for Alcon, the divestment comes as Novartis continues to figure out what to do with the unit, where sales have stagnated for years before showing a small jump in the last quarter, up 3% to $1.5 billion.

Some analysts remain skeptical that the first-quarter results are an indication of a sustained revival. Novartis CEO Joe Jimenez has said he would announce by year end what he thinks the company might do with the unit, indicating that if it could report a few quarters like that, a spin-off might be in order.

Of course, the ultimate decision may now fall to Vas Narasimhan, who this month was named to become Novartis CEO following Jimenez’s announcement that he would retire at the end of January. Narasimhan currently serves as Novartis’ head of drug development.

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.